期刊文献+

干扰素-α转染HepG2细胞内下调表达基因的筛选

Screening the down-regulated genes in HepG2 cells transfected by IFN-α
暂未订购
导出
摘要 目的筛选干扰素-α真核表达质粒转染HepG2细胞后细胞内表达下调的基因,以进一步探讨干扰素-α作用的分子生物学机制。方法将pcDNA3.1(-)-IFN-α以及pcDNA3.1(-)空载体分别转染肝母细胞瘤HepG2细胞系,用抑制性消减杂交技术筛选pcDNA3.1(-)-IFN-α转染HepG2细胞内表达下调的基因。以pcDNA3.1(-)转染组细胞作为tester,pcDNA3.1(-)-IFN-α转染组作为driver,建立消减文库,随机挑选阳性克隆,测序并进行序列比对,得到下调表达的基因。应用RT-PCR技术,进一步证明IFN-α对Hsp90的下调表达作用关系。结果成功构建了IFN-α真核表达质粒转染HepG2细胞后表达下调的cDNA消减文库。从文库中随机挑选克隆,测序并进行生物信息学分析后,得到下调表达的基因有铁蛋白,热休克蛋白90,S-腺苷甲硫氨酸脱羧酶1,真核翻译延伸因子1β,信号序列受体β(SSR2),组织因子路径抑制子,RAD23同源物B。RT-PCR进一步表明,IFN-α真核表达质粒转染的HepG2细胞内Hsp90mRNA表达水平下调。结论应用SSH技术成功构建了pcDNA3.1(-)-IFN-α转染的HepG2细胞内表达下调的cDNA消减文库,并筛选出下调表达基因,半定量RT-PCR表明IFN-α对Hsp90mRNA具有下调表达作用。为进一步阐明IFN-α作用的分子生物学机制提供了重要的理论依据。 Objective To screen the down-regulated genes in HepG2 cells transfected by pcDNA3.1(-)-IFN-α to further investigate the biological mechanism of IFN-α Methods PeDNA3. 1 (-)-IFN-α was transfected into HepG2 cells as treatment group and the PeDNA3. 1(-) transfected cells as the control to perform suppression subtractive hybridization (SSH). The subtractive library for down- regulated genes was obtained when peDNA3. 1 (-) transfccted HepG2 as tester arid peDNA3. 1 (-)-IFN-α transfected cells as driver. A housekeeping gene, G3PDH, was used to estimate the subtractive efficiency. Genes with lower expressions in IFN-a transfected HepG2 cells were obtained from the library after being randomly sequenced and analyzed. Among the obtained genes, regulation of IFN-α on heat shock 90kD (Hsp90) mRNA was further investigated by RT-PCR Results G3PDH was subtracted efficiently indicating that the subtraetive library was constructed successfully. 50 positive clones were randomly isolated for PCR identification. Results showed that most of the plasmids in the clones contained 200-1000bp inserts. The down-regulated genes obtained were as follows: eukaryotic translation elongation factor 1 beta, ferritin, RAD23 homolog B, signal sequence receptor 2 (SSR2), tissue factor pathway inhibitor, heat shock 90kD protein 1, and adenosylmethionine decarboxylase 1. RT-PCR showed that hsp90 mRNA had a reduced expression in pcDNA3. 1 (-)-IFN-α transfected HepG2 cells Conclusion The down-regulated cDNA subtractive library in HepG2 cells after pcDNA3. 1 (-)-IFN-α transfection was constructed successfully. IFN-α could down-regulate the hsp90 mRNA expression.
出处 《解放军医学杂志》 CAS CSCD 北大核心 2007年第1期35-38,共4页 Medical Journal of Chinese People's Liberation Army
关键词 干扰素-Α 细胞系 肿瘤 抑制性消减杂交技术 interferon-alpha cell line, tumor suppression subtraetive hybridization
  • 相关文献

参考文献10

  • 1Jonasch E,Haluska FG.Interferon in oncological practice:review of interferon biology,clinical applications,and toxicities.Oncologist,2001,6:34
  • 2曲建慧,成军,张黎影,徐东平,钟彦伟,刘妍,王琳,戴久增,张玲霞.抑制性消减杂交技术筛选干扰素α转染HepG2细胞中上调的表达基因[J].中国新药与临床杂志,2006,25(1):21-25. 被引量:1
  • 3Sandyd D,Zhou AM,Bryan RG,et al.Identification of genes differentially regulated by interferon alpha,beta,or gamma using oligonucleotide arrays.Proc Natl Acad Sci USA,1998,95(26):15623
  • 4Takeo M,Kobayashi Y,Fujita N,et al.Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C.Gastroenterol Hepatol,2005,20:562
  • 5Metwally MA,Zein CO,Zein NN.Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection.Am J Gastroenterol,2004,99(3):286
  • 6Hofer H,Osterreicher C,Jessner W,et al.Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C.J Hepatol,2004,40:1018
  • 7Distante S,Bjoro K,Hellum KB,et al.Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection.Liver,2002,22(3):269
  • 8Kee K,Vujcic S,Merali S,et al.Metabolic and antiproliferative consequences of activated polyamine catabolism in LNCaP prostate carcinoma cells.J Biol Chem,2004,279:27050
  • 9Hu X,Washington S,Verderame MF,et al.Biological activity of the S-adenosylmethionine decarboxylase inhibitor SAM486A in human breast cancer cells in vitro and in vivo.Int J Oncol,2000,25:1831
  • 10Isaacs JS,Xu W,Neckers L.Heat shock protein 90 as a molecular target for cancer therapeutics.Cancer Cell,2003,3(3):213

二级参考文献14

  • 1STARK GR, KERR IM. WILLIAMS BR, et al. How veils respond to interferons[J]. Annu Rev Biochem, 1998,67:227-264.
  • 2SAMUEL CE. Anliviral actions of interferons[J]. Clin Mierobiol Rev, 2001,14(4) :778-809.
  • 3NAKA T, FUJIMOTO M, KISHIMOTO T. Negative regulation of cytokine signaling: STAT-indueed STAT inhibitor[J]. Trends Biochem Sci, 1999,24(10) :394-398.
  • 4KEELING PJ, INAGAKI. A class of eukaryotie GTPase with a punctate distribution suggesting multiple functional replacements of translation elongation factor lalpha [J]. Proe Natl Aeact Sci USA,2004,101 (43) : 15380-15385.
  • 5LAMBERTI A, CARAGLIA M, LONGO O, et al. The translation elongation factor IA in tumorigenesis,signal transduction and apoptosis: review article[J]. Amino Acids,2004,26(4):443-448.
  • 6RIEBELING C ,ALLEGOOD JC,WANG E,et al. Two mammalian longevity assurance gene (LAGI)family members,trhl and trh4,regulate dihydroceramide synthesis using different fatty aeyl-CoA donors[J]. J Biol Chem. 2003,278 (44) :43452-43459.
  • 7VENKATARAMAN K, RIEBELING C, BODENNEC J, et al.Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAGI),regulates N-stearoyl-sphinganine (C18-(dihydro) ceramide)synthesis in a fumonisin B1-independent manner in mammal- ian cells[J]. J Biol Chem, 2002, 277(38):35642-35649.
  • 8JAFFREZOU JP, LAURENT G. Ceramide:a new target in anticancer research? [J]. Bull Cancer, 2004, 91 (5) :E133-E161.
  • 9SUNG YK, HWANG SY, FAROOQ M, et al. Growth promotion of HepG2 hepatoma cells by antisense-mediated knockdown of glypican-3 is independent of insulin-like growth factor 2 signaling[J]. Exp Mol Med, 2003, 35(4):257-262.
  • 10HIPPO Y, WATANABE K, WATANABE A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma [J]. Cancer Res,2004, 64(7) :2418-2423.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部